Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 15;15(6):791-792.
doi: 10.5009/gnl210508.

Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype

Hyuk Yoon  1
Affiliations
Editorial

Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype

Hyuk Yoon. Gut Liver. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Comment on

References

    1. Moon JS. Clinical aspects and treatments for pediatric inflammatory bowel disease. Intest Res. 2019;17:17–23. doi: 10.5217/ir.2018.00139. - DOI - PMC - PubMed
    1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–1583. doi: 10.1053/j.gastro.2020.12.031. - DOI - PubMed
    1. Kerur B, Machan JT, Shapiro JM, et al. Biologics delay progression of Crohn's disease, but not early surgery, in children. Clin Gastroenterol Hepatol. 2018;16:1467–1473. doi: 10.1016/j.cgh.2018.02.027. - DOI - PubMed
    1. Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 2019;17:285–310. doi: 10.5217/ir.2019.00026. - DOI - PMC - PubMed
    1. Kim HJ, Oh SH, Lee SH, et al. Risk factors for disease behavior evolution and efficacy of biologics in reducing progression in pediatric patients with nonstricturing, nonpenetrating Crohn's disease at diagnosis: a single-center experience in Korea. Gut Liver. 2021;15:851–857. doi: 10.5009/gnl20279. - DOI - PMC - PubMed